- Monday, May 16, 2022
- IPC GENERAL
- Industry
Bristol Myers Squibb (BMS) presented new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis. This data adds to the growing amount of evidence proving Deucravacitinib could be a new oral treatment option for moderate to severe plaque psoriasis. Deucravacitinib is currently under regulatory review in multiple regions, including the United States, Europe, and Japan. If approved, it would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved to treat any disease.
